/
DOI:
https://doi.org/10.54133/ajms.v10i1.2688الكلمات المفتاحية:
Disease severity، miR-146a، Psoriasis ، Real-time PCRالملخص
/
التنزيلات
المراجع
Prema SS, Shanmugamprema D. Systemic psoriasis: From molecular mechanisms to global management strategies. Clin Rev Allergy Immunol. 2025;68(1):79. doi: 10.1007/s12016-025-09089-4. DOI: https://doi.org/10.1007/s12016-025-09089-4
Jasim SA, Abbas M, Mustafa ET, Abdulqader SK. Correlation between psoriasis severity and dyslipidaemia in Iraqi patients. Scr Medica. 2025;56(3):451–459 doi: 10.5937/scriptamed56-57843. DOI: https://doi.org/10.5937/scriptamed56-57843
Orzan OA, Tutunaru CV, Ianoși SL. Understanding the intricate pathophysiology of psoriasis and related skin disorders. Int J Mol Sci. 2025;26(2):749. doi: 10.3390/ijms26020749. DOI: https://doi.org/10.3390/ijms26020749
Schön MP. Adaptive and innate immunity in psoriasis and other inflammatory disorders. Front Immunol. 2019;10:1764. doi: 10.3389/fimmu.2019.01764. DOI: https://doi.org/10.3389/fimmu.2019.01764
Mehta H, Narang T, Dogra S, Handa S, Hatwal J, Batta A. Cardiovascular considerations and implications for treatment in psoriasis: An updated review. Vasc Health Risk Manag. 2024;20:215–229. doi: 10.2147/VHRM.S464471. DOI: https://doi.org/10.2147/VHRM.S464471
Walsh JA, Jones H, Mallbris L, Duffin KC, Krueger GG, Clegg DO, et al. The physician global assessment and body surface area composite tool is a simple alternative to the Psoriasis Area and Severity Index for assessment of psoriasis: post hoc analysis from PRISTINE and PRESTA. Psoriasis (Auckl). 2018;8:65-74. doi: 10.2147/PTT.S169333. DOI: https://doi.org/10.2147/PTT.S169333
Gao Y, Xu T, Wang Y, Hu Y, Yin S, Qin Z, et al. Pathophysiology and treatment of psoriasis: From clinical practice to basic research. Pharmaceutics. 2025;17(1):56. doi: 10.3390/pharmaceutics17010056. DOI: https://doi.org/10.3390/pharmaceutics17010056
Gordon KB, Reich K, Crowley JJ, Korman NJ, Murphy FT, Poulin Y, et al. Disease activity and treatment efficacy using patient-level Psoriasis Area and Severity Index scores from tildrakizumab phase 3 clinical trials. J Dermatolog Treat. 2022;33(1):219-228. doi: 10.1080/09546634.2020.1747590. DOI: https://doi.org/10.1080/09546634.2020.1747590
Ben Abdallah H, Emmanuel T, Bregnhøj A, Johansen C, Iversen L. Early intervention and disease memory in psoriasis: A literature review. JEADV Clin Pract. 2022;1(4):307–316. doi: 10.1002/jvc2.63. DOI: https://doi.org/10.1002/jvc2.63
Jiang X, Shi R, Ma R, Tang X, Gong Y, Yu Z, et al. The role of microRNA in psoriasis: A review. Exp Dermatol. 2023;32(10):1598-1612. doi: 10.1111/exd.14871. DOI: https://doi.org/10.1111/exd.14871
Leal B, Carvalho C, Ferreira AM, Nogueira M, Brás S, Silva BM, et al. Serum levels of miR-146a in patients with psoriasis. Mol Diagn Ther. 2021;25(4):475-485. doi: 10.1007/s40291-021-00531-9. DOI: https://doi.org/10.1007/s40291-021-00531-9
Salvi V, Gianello V, Tiberio L, Sozzani S, Bosisio D. Cytokine targeting by miRNAs in autoimmune diseases. Front Immunol. 2019;10(JAN):15. doi: 10.3389/fimmu.2019.00015. DOI: https://doi.org/10.3389/fimmu.2019.00015
Ho PY, Huang YC. MicroRNA-146a signature in psoriasis: A systematic review and meta-analysis. Mol Diagn Ther. 2024;28(4):379–388. doi: 10.1007/s40291-024-00714-0. DOI: https://doi.org/10.1007/s40291-024-00714-0
Gilyazova I, Asadullina D, Kagirova E, Sikka R, Mustafin A, Ivanova E, et al. MiRNA-146a-A key player in immunity and diseases. Int J Mol Sci. 2023;24(16):12767. doi: 10.3390/ijms241612767. DOI: https://doi.org/10.3390/ijms241612767
Luk AH, Yu R, Yang I. The role of miR-146a in immune regulation and psoriasis. Int J Mol Sci. 2021;22(18):9981. doi: 10.3390/ijms22189981. DOI: https://doi.org/10.3390/ijms22189981
Gavra DI, Kósa D, Pető Á, Józsa L, Ujhelyi Z, Fehér P, et al. Exploring the correlation between the PASI and DLQI scores in psoriasis treatment with topical ointments containing Rosa × damascena Mill. extract. Pharmaceuticals (Basel). 2024;17(8):1092. doi: 10.3390/ph17081092. DOI: https://doi.org/10.3390/ph17081092
Zheng J, Lu Y, Xiao J, Duan Y, Zong S, Chen X, et al. Pan-HDAC inhibitors augment IL2-induced proliferation of NK cells via the JAK2-STAT5B signaling pathway. Int Immunopharmacol. 2023;116:109753. doi: 10.1016/j.intimp.2023.109753. DOI: https://doi.org/10.1016/j.intimp.2023.109753
Xiao W, Hu S, Zou X, Cai R, Liao R, Lin X, et al. Lectin receptor-like kinase LecRK-VIII.2 is a missing link in MAPK signaling-mediated yield control. Plant Physiol. 2021;187(1):303-320. doi: 10.1093/plphys/kiab241. DOI: https://doi.org/10.1093/plphys/kiab241
Joyce CE, Zhou X, Xia J, Ryan C, Thrash B, Menter A, et al. Deep sequencing of small RNAs from human skin reveals major alterations in the psoriasis miRNAome. Hum Mol Genet. 2011;20(20):4025-4040. doi: 10.1093/hmg/ddr331. DOI: https://doi.org/10.1093/hmg/ddr331
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods. 2001;25(4):402–408. doi: 10.1006/meth.2001.1262. DOI: https://doi.org/10.1006/meth.2001.1262
Shen H, Wang D, Zhan M, Ding H, Zhao H. MicroRNA-146a and microRNA-146b deficiency correlates with exacerbated disease activity, and their longitude increment relates to etanercept response in psoriasis patients. J Clin Lab Anal. 2022;36(2):e24198. doi: 10.1002/jcla.24198. DOI: https://doi.org/10.1002/jcla.24198
Zhang R, Wei Y, Wang T, Nie X, Shi Z, Deng Y, et al. Exosomal miRNAs in autoimmune skin diseases. Front Immunol. 2023;14:1307455. doi: 10.3389/fimmu.2023.1307455. DOI: https://doi.org/10.3389/fimmu.2023.1307455
Srivastava A, Nikamo P, Lohcharoenkal W, Li D, Meisgen F, Xu Landén N, et al. MicroRNA-146a suppresses IL-17-mediated skin inflammation and is genetically associated with psoriasis. J Allergy Clin Immunol. 2017;139(2):550-561. doi: 10.1016/j.jaci.2016.07.025. DOI: https://doi.org/10.1016/j.jaci.2016.07.025
Liao Z, Zheng R, Shao G. Mechanisms and application strategies of miRNA 146a regulating inflammation and fibrosis at molecular and cellular levels (Review). Int J Mol Med. 2023;51(1):6. doi: 10.3892/ijmm.2022.5210. DOI: https://doi.org/10.3892/ijmm.2022.5210
Yang Z, Zeng B, Tang X, Wang H, Wang C, Yan Z, et al. MicroRNA-146a and miR-99a are potential biomarkers for disease activity and clinical efficacy assessment in psoriasis patients treated with traditional Chinese medicine. J Ethnopharmacol. 2016;194:727-732. doi: 10.1016/j.jep.2016.08.028. DOI: https://doi.org/10.1016/j.jep.2016.08.028
Xia P, Fang X, Zhang ZH, Huang Q, Yan KX, Kang KF, et al. Dysregulation of miRNA146a versus IRAK1 induces IL-17 persistence in the psoriatic skin lesions. Immunol Lett. 2012;148(2):151-162. doi: 10.1016/j.imlet.2012.09.004. DOI: https://doi.org/10.1016/j.imlet.2012.09.004
Luo L. Deciphering the complexity of psoriasis : non-coding RNAs and cellular interactions. Karolinska Institutet. Thesis; 2023. Available at: https://hdl.handle.net/10616/48830.
Man AM, Orăsan MS, Hoteiuc OA, Olănescu-Vaida-Voevod MC, Mocan T. Inflammation and psoriasis: A comprehensive review. Int J Mol Sci. 2023;24(22):16095. doi: 10.3390/ijms242216095. DOI: https://doi.org/10.3390/ijms242216095
Matei-Man AM, Vesa ȘC, Pușcaș AD, Orăsan MS, Homorozeanu B, Candrea E, et al. Assessment of TNF-α, IL-12/23, and IL-17 in psoriasis: Only TNF-α reflects clinical response after 12 weeks of biologic treatment. Curr Issues Mol Biol. 2025;47(5):368. doi: 10.3390/cimb47050368. DOI: https://doi.org/10.3390/cimb47050368
Zhang W, Yi X, Guo S, Shi Q, Wei C, Li X, et al. A single-nucleotide polymorphism of miR-146a and psoriasis: an association and functional study. J Cell Mol Med. 2014;18(11):2225-34. doi: 10.1111/jcmm.12359. DOI: https://doi.org/10.1111/jcmm.12359
Tabl HA, Sabry HH. Association between single-nucleotide polymorphism of miR-146a and psoriasis. Egypt J Med Microbiol. 2019;28(1):65–71. doi: 10.21608/EJMM.2019.282405. DOI: https://doi.org/10.21608/ejmm.2019.282405
Jasim SA, Mustafa ET, Abdulqader SK. Comparative efficacy of biologics vs. conventional therapies in psoriasis: A meta-analysis of a decade of progress from 2015 to 2025. Al-Rafidain J Med Sci. 2025;9(2):296–306. doi: 10.54133/ajms.v9i2.2483. DOI: https://doi.org/10.54133/ajms.v9i2.2483
التنزيلات
منشور
كيفية الاقتباس
إصدار
القسم
الرخصة
الحقوق الفكرية (c) 2026 Al-Rafidain Journal of Medical Sciences
هذا العمل مرخص بموجب Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Published by Al-Rafidain University College. This is an open access journal issued under the CC BY-NC-SA 4.0 license (https://creativecommons.org/licenses/by-nc-sa/4.0/).
